ALYFTREK - FDA NDA approval - 2024-12-20 скачать в хорошем качестве

ALYFTREK - FDA NDA approval - 2024-12-20

This video describes the NDA approval of ALYFTREK for treatment of cystic fibrosis in patients with an age of at least 6 with at least one responsive mutation in the CFTR gene. ALYFTREK contains three active pharmaceutical ingredients - vanzacaftor, tezacaftor, and deutivacaftor. ALYFTREK was approved by the U.S. FDA on December 20, 2024. The sponsor of the NDA was Vertex Pharmaceuticals of Boston, MA The structural features, ADME/PK, and key safety risks of ALYFTREK are discussed. prescribing information: https://www.accessdata.fda.gov/drugsa... This video was created for academic purposes. The creator of the video is not a medical doctor, has no financial interests in the drug sponsor, and has no relationship with the U.S. FDA.